Supplements, Research, AML Herbal Regimen
Tumeric (curcumin) (Thank You Margaret!)
Review:
Curcumin: from ancient medicine to current clinical trials.
AML:
2002 Dec
Clinical study on the effect of curcumin on cell cycle proteins and regulating proteins of apoptosis in acute myelogenous leukemia
2004
Mechanisms of proapoptotic properties of curcumin in chronic and acute myeloid leukemia
AntiCancer:
1998
Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells.
2001
Study on circumen-oligonucleotide conjugate as probable anti-cancer agent
2003 Jan
Anticancer potential of curcumin: preclinical and clinical studies.
2005 Mar
Induction of apoptosis by curcumin and its implications for cancer therapy.
2005 Sep
Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis
2006 Jul
Multiple Molecular Targets in Cancer Chemoprevention by Curcumin
2008 Jul
New mechanisms and therapeutic potential of curcumin for colorectal cancer.
2008 Aug
Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells.
Operation:
1995 Oct
Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]
1997
Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin.
2002 Dec
Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation.
2005 Jun
Modulatory Effects of Curcumin and Curcumin Analog on Circulatory Lipid Profiles During Nicotine-Induced Toxicity in Wistar Rats
2005 Aug
Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
2006 Jan
Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation.
2007
Molecular targets of curcumin.
2008 Apr
Opposing effects of curcuminoids on serum stimulated and unstimulated angiogenic response.
Blood-Brain Barrier:
2007 Apr
Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage
2005 Feb
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo
Histone HypoAcetylation: (Histone acetyltransferase (HAT) and histone deacetylase (HDAC))
1999 Sep
Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy
2003 Oct
Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype.
2005 May
Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation.
2005 Dec
Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3–Dependent Expression of MHC Class I–Related Chain A and B
2005 Jan
Histone deacetylase inhibitors.
2005 Apr
Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
2006 Mar
Curcumin is an inhibitor of p300 histone acetylatransferase.
2006 Jan
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
2007
Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
2008 Jul
Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.
2008 Oct
Histone deacetylase inhibitors as novel anticancer therapeutics
Histone "Hyper"Acetylation: (an good effect dampened by Curcumin?)
2008 Jun
Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B).
Advocacy:
2005 Jan
A Report On Curcumin's Anti-Cancer Effects
2007
Curcumin - developing a following in American hospitals
BioAvailability:
2000 Oct
Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma.
2005 Jan
Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
2007 Jul
Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine.
2007 Jan
Curcuminoids form reactive glucuronides in vitro.
2007 Aug
Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases.
With Radiation:
2007
Radioprotection and radiosensitization by curcumin.
Cystic Fibrosis:
2004 Apr
Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects.
2006 May
Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network.
Clinical Trials:
2007 Jul
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer.
Other Research and Analysis:
#1
M.D. Anderson FAQ
#2
M.D. Anderson - Natural Standard
#3
Oregon State University: Linus Pauling Institute
#4
Sloan Kettering
#5
NCCAM Herbs